Zusammenfassung
Subkutane Apomorphininjektionen sind eine wertvolle und effektive
Therapie für Parkinsonpatienten, die trotz optimierter oraler Therapie
noch wiederholte „Off”-Phasen zeigen. Die durchschnittliche
tägliche „Off”-Zeit kann halbiert werden und die noch
bestehenden „Off”-Perioden sind milder ausgeprägt. Diese
Effekte sind auch über längere Zeit stabil und es gibt keinen Anhalt
für eine Toleranzentwicklung. Die Nebenwirkungen sind meistens gering
ausgeprägt. Der beste Effekt wird erreicht, wenn Apomorphin bei relativ
jungen, aktiven und kognitiv nicht eingeschränkten Patienten eingesetzt
wird. Subkutane Apomorphininjektionen können oft das Weiterarbeiten und
das Führen eines normalen Lebens ermöglichen. Apomorphin bietet eine
zuverlässige Möglichkeit, schnell aus einer „Off”-Phase
zu kommen. Dies führt zu mehr Unabhängigkeit und Selbstvertrauen bei
den Betroffenen.
Abstract
Apomorphine as subcutaneous injections offers a valuable and
effective treatment alternative for Parkinson patients with oral
medication-resistant „off” phases. Its efficacy is stable during
long-term therapy, with no signs of patient tolerance. Adverse events are
usually mild. The best results are obtained with relatively young, active, and
cognitively intact patients. Intermittent s. c. apomorphine therapy can
improve the patients' possibilities to continue to work and to live a
normal social life, by offering increased freedom and self-confidence through
a
reliable, quick rescue from the disabling medication-resistant
„off” phases.
Schlüsselwörter
Apomorphin - Injektion - Subkutan - Parkinson - Dopaminagonist
Keywords
apomorphine - injection - subcutaneous - Parkinson - dopamine agonist
Literatur
- 1
LeWitt P A.
Subcutaneously administered apomorphine: pharmacokinetics and
metabolism.
Neurology.
2004;
62
(S 04)
S8-11
- 2
Pietz K, Hagell P, Odin P.
Subcutaneous apomorphine in late stage Parkinson's
disease: A long-term follow-up.
J Neurol Neurosurg Psychiatry.
1998;
65
709-716
- 3
Hagell P, Odin P.
Apomorphine in the treatment of Parkinson's
disease.
J Neurosci Nurs.
2001;
33
21-38
- 4
Poewe W, Kleedorfer B, Wagner M et al.
Side-effects of subcutaneous apomorphine in Parkinson's
disease.
Lancet.
1989;
i (8646)
1084-1085
- 5
Pollak P, Champay A S, Gaio J M et al.
Administration sous-cutanée d'apomorphine dans
les fluctuations motrices de la maladie de Parkinson.
Rev Neurol (Paris).
1990;
146
116-122
- 6
Kempster P A, Iansek R, Larmour I.
Intermittent subcutaneous apomorphine injection treatment for
Parkinson's disease.
Aust NZ J Med.
1991;
21
314-318
- 7
Hughes A J, Bishop S, Kleedorfer B et al.
Subcutaneous apomorphine in Parkinson's disease:
Response to chronic administration for up to five years.
Mov Disord.
1993;
8
165-170
- 8
Merello M, Leiguarda R.
Tratamiento de las fluctuationes motoras de la enfermedad de
parkinson con inyecciones subcutaneas de apomorfina.
Medicina (B Aires).
1995;
55
5-10
- 9
Esteban-Munoz J, Marti M J, Marin C et al.
Long-term treatment with intermittent intranasal or
subcutaneous apomorphine in patients with levodopa-related motor
fluctuations.
Clin Neuropharmacol.
1997;
20
245-252
- 10
Östergaard L, Werdelin L, Odin P et al.
Pen injected apomorphine against off phenomena in late
Parkinson's disease: a double blind, placebo controlled study.
J Neurol Neurosurg Psychiatry.
1995;
58
681-687
- 11
Dewey R B, Hutton T, LeWitt A et al.
A randomized, double-blind, placebo-controlled trial of
subcutaneously injected Apomorphine for parkinsonian off-state events.
Arch Neurol.
2001;
58
1385-1392
- 12
Factor S A.
Literature review: Intermitten subcutaneous apomorphine
therapy in Parkinson's disease.
Neurology.
2004;
62
S12-S17
- 13
Stacy M.
Apomorphine: North american clinical experience.
Neurology.
2004;
62
S18-S21
- 14
Pfeiffer R F, Gutmann L, Hull K L the APO302 study investigators et al.
Continued efficacy and safety of subcutaneous apomorphine in
patients with advanced Parkinson's disease.
Parkinsonism Relat Disord.
2007;
13
93-100
- 15
Stacy M, Silver D.
Apomorphine for the acute treatment of „off”
episodes in Parkinson's disease.
Parkinsonism Relat Disord.
2008;
14
85-92
- 16
Pahwa R, Koller W C, Trosch R M APO303 study investigators et al.
Subcutaneous apomorphine in patients with advanced
Parkinson's disease: A dose-escalation study with randomized,
double-blind, placebo-controlled crossover evaluation of a single dose.
J Neurol Sci.
2007;
258
137-143
- 17
Trosch R M, Silver D, Bottini P B.
Intermittent subcutaneous apomorphine therapy for
„off” episodes in Parkinson's disease: a 6-month open-label
study.
CNS Drugs.
2008;
22
519-527
- 18
Düby S E, Cotzias G C, Papavasiliou P S et al.
Injected apomorphine and orally administered levodopa in
parkinsonism.
Arch Neurol.
1972;
27
474-480
- 19
Victor J FS, Pollak P, Gervason C L et al.
Levodopa-induced diphasic dyskinesia improved by subcutaneous
apomorphine.
Mov Disord.
1992;
7
283-284
- 20
Lees A J.
Dopamine agonists in Parkinson's disease: a look at
apomorphine.
Fundam Clin Pharmacol.
1993;
7
121-128
- 21
Frankel J P, Lees A J, Kemster P A et al.
Subcutaneous apomorphine in the treatment of Parkinson's
disease.
J Neurol Neurosurg Psychiatry.
1990;
53
96-101
- 22
Factor S A, Brown D L, Molho E S.
Subcutaneous apomorphine injections as a treatment for
intractable pain in Parkinson's disease.
Mov Disord.
2000;
15
167-169
- 23
Tison F, Wiart L, Guatterie M et al.
Effects of central dopaminergic stimulation by apomorphine on
swallowing disorders in Parkinson's disease.
Mov Disord.
1996;
11
729-732
- 24
Edwards L L, Quigley E MM, Harned R K et al.
Defecatory function in Parkinson's disease: response to
apomorphine.
Ann Neurol.
1993;
33
490-493
- 25
Christmas T J, Kempster P A, Chapple C R et al.
Role of subcutaneous apomorphine in Parkinsonian voiding
dysfunction.
Lancet.
1988;
2
1451-1453
- 26
Tyne H L, Parsons J, Sinnott A et al.
A 10 year retrospective audit of long-term apomorphine use in
Parkinson's disease.
J Neurol.
2004;
251
1370-1374
- 27
LeWitt P A, Ondo W G, Van Lunen B et al.
Open-label study assessment of safety and adverse effects of
subcutaneous apomorphine injections in treating „off” episodes in
advanced Parkinson disease.
Clin Neuropharmacol..
2009;
32
89-93
- 28
Chen J J, Obering C.
A review of intermittent subcutaneous apomorphine injections
for the rescue management of motor fluctuations associated with advanced
Parkinson's disease.
Clin Ther.
2005;
27
1710-1724
- 29
Deleu D, Hanssens Y, Northway M G.
Subcutaneous Apomorphine: An evidence-based review of its use
in Parkinson's disease.
Drugs Aging.
2004;
21
687-709
- 30
Gunzler S A.
Apomorphine in the treatment of Parkinson disease and other
movement disorders.
Expert Opin Pharmacother.
2009;
10
1027-1038
- 31
Haq I U, Lewitt P A, Fernandez H H.
Apomorphine therapy in Parkinson's disease: a
review.
Expert Opin Pharmacother.
2007;
8
2799-2809
- 32
Kolls B J, Stacy M.
Apomorphine: a rapid rescue agent for the management of motor
fluctuations in advanced Parkinson disease.
Clin Neuropharmacol.
2006;
29
292-301
- 33
Menon R, Stacy M.
Apomorphine in the treatment of Parkinson's
disease.
Expert Opin Pharmacother.
2007;
8
1941-1950
- 34
Obering C D, Chen J J, Swope D M.
Update on apomorphine for the rapid treatment of hypomobility
(„off”) episodes in Parkinson's disease.
Pharmacother.
2006;
26
840-852
- 35
O'Sullivan J D, Lees A J.
Use of apomorphine in Parkinson's disease.
Hosp Med.
1999;
60
816-820
- 36
Poewe W, Wenning G K.
Apomorphine: an underutilized therapy for Parkinson's
disease.
Mov Disord.
2000;
15
789-794
- 37
Trenkwalder C, Boesch S, Ceballos-Baumann A et al.
Intermittent apomorphine injections as rescue therapy for
advanced Parkinson's disease: Consensus statement.
Nervenarzt.
2008;
79
475-479
Prof. Dr. med. Per Odin
Abt. Neurologie, Klinikum-Bremerhaven
Postbrookstr. 103
27574 Bremerhaven
eMail: per.odin@klinikum-bremerhaven.de
